

REVIEW OF DECISIONS

BOARD MEETING

24-25 July 2025, Geneva, Switzerland

Decision 1: Consent Agenda: Board and Committee Appointments

The Gavi Alliance Board:

Reappointed Yibing Wu, as an Unaffiliated Board Member, effective 1 November 2025 and until 30 October 2026.

Decision 2: Consent Agenda: Board Committee Chair Appointment

The Gavi Alliance Board:

Reappointed Yibing Wu, as Chair of the Investment Committee, effective 1 November 2025, and until 31 December 2025.

Decision 3: Consent Agenda: Board Vice Chair Appointment

The Gavi Alliance Board:

- a) **Reappointed Omar Abdi** as Vice Chair of the Board with individual signatory authority, effective 1 January 2026 and until 31 December 2027
- b) **Reappointed Omar Abdi** as Chair of the Governance Committee, effective 1 January 2026 and until 31 December 2027

Decision 4: Consent Agenda: Independent Review Committee Terms of Reference: Request for Secretariat Led Exceptional Grant Extensions Approval

The Gavi Alliance Board:

Approved, exceptionally, the proposed time-bound waiver to the Independent Review Committee (IRC) Terms of Reference, authorising the Secretariat to recommend for approval country grant extension requests during the transition from Gavi 5.1 to 6.0.

Decision 5: Consent Agenda: Speak up Policy

The Gavi Alliance Board:

Approved the Speak Up Policy as set out in Annex A to Doc 01d.

Decision 6: Consent Agenda: Retirement of the Gavi Alliance Stock Gift Policy

The Gavi Alliance Board:

Retired with immediate effect the Gavi Alliance Stock Gift Policy attached as Annex B to Doc 01d.

Decision 7: Consent Agenda: Governance Pathways for Next Generation Vaccines

The Gavi Alliance Board:

- a) **Approved** the revised governance pathways to evaluate next generation vaccines targeting already-supported pathogens for potential inclusion on the Gavi “product menu” attached as Annex C to Doc 01d; and
- b) **Noted** that the revised governance pathways include an assessment of the relevance of the next generation vaccines to Gavi countries, the anticipated budget impact and programmatic, regulatory, demand and market health benefits and risks, an investment case presented to the Programme and Policy Committee and Board if these risks and budget impact are considered material, and an assessment of whether the vaccines meet Gavi’s Product Portfolio Management principles for inclusion on the Gavi “product menu”.

Decision 8: Consent Agenda: Health Systems Strategy

The Gavi Alliance Board:

Approved the Health Systems Strategy attached as Annex D to Doc 01d.

Decision 9: Consent Agenda: Measurement, Evaluation and Learning for Gavi 6.0

The Gavi Alliance Board:

Approved the mission and strategy performance monitoring indicators for the 2026-2030 strategy attached as Annex E to Doc 01d.

Decision 10: Financial Update, incl forecast (1/2)

The Gavi Alliance Board:

- a) **Noted** that the Audit and Finance Committee reviewed the recommendations to be made to the Programme and Policy Committee and concluded that there are no financial implications for the Gavi 5.1 strategic period;
- b) **Approved** the Gavi 5.1 Financial Forecast (2021-2025) of Qualifying Resources of US\$ 13.6 billion and Forecast Expenditure of US\$ 13.4 billion;
- c) **Noted** that the financial forecast reflects the risk that reduced partner and country delivery capacity will impact Gavi programmes, at an estimated value of US\$ 214 million in 2025. In the event that the risk of lower vaccine demand does not materialise, the Secretariat is **authorised** to fund these programmes in line with country plans and up to a total Gavi 5.1 Expenditure of US\$ 13.6 billion;
- d) **Noted** that a number of risks and opportunities in relation to the Gavi 5.1 financial forecast have been identified which may lead to additional changes in the forecast;

Decision 10: Financial Update, incl forecast (2/2)

- e) **Noted** that in light of the uncertainty of the environment, no additional commitments beyond existing programmatic commitments will be made against the forecasted net available funds of US\$ 185 million;
- f) **Noted** the remaining balance on the COVAX Advance Market Commitment Pandemic Vaccine Pool is US\$ 1.9 billion.

Decision 11: Funding Policy Review (1/5)

The Gavi Alliance Board:

- a) **Approved** the revised Eligibility and Transition Policy attached as Annex A to Doc 06;
- b) **Approved** the revised Co-financing Policy attached as Annex B to Doc 06;
- c) **Approved** the revised Health Systems and Immunisation Strengthening (HSIS) Policy attached as Annex C to Doc 06;

Decision 11: Funding Policy Review (2/5)

As discussed by the Gavi Alliance Board in its Gavi 6.0 recalibration, the Board agreed to:

- d) **Rescind** the following items, approved in December 2024 (Decision 9: ELTRACO, including Catalytic Phase):
- For countries in preparatory and accelerated transition, establishing an introductory co-financing cap of 35% for all new vaccines, with the exception of measles and measles-rubella;
 - Providing countries in accelerated transition (AT) with eight years of vaccine support for all new vaccines introduced during AT, regardless of when during the AT phase they are introduced;
 - Providing five years of additional programmatic support to reinforce programmatic capacities for countries post-AT who meet the specified criteria;
 - The backsliding objective and support under the Catalytic Phase; and
 - Under the Catalytic Phase, applying the proposed performance indicators and prioritisation criteria in determining eligibility for Targeted Intervention support to Former-Gavi-eligible countries experiencing backsliding;

Decision 11: Funding Policy Review (3/5)

- e) **Approve** co-financing requirements as from 2026 for Gavi-supported vaccines for use in Gavi supported Campaigns, including One-Time Immunisation Campaigns and Periodic Follow-up Campaigns, excluding Outbreak Response Campaigns, as follows:
- Co-financing requirement for initial self-financing countries at 5% of the total price of vaccine doses;
 - Co-financing requirement for preparatory transition countries at 10% of the total price of vaccine doses; and
 - Co-financing requirement for accelerated transition countries at 20% of the total price of vaccine doses;

Decision 11: Funding Policy Review (4/5)

- f) **Approve** a transition approach for Fully Self-Financing (FSF) countries to assume full funding of their IPV and Hexavalent vaccine programmes, to be reviewed by the Programme and Policy Committee no later than 2028.

This **rescinds** the exceptional co-financing arrangements for polio as they apply to FSF countries, as endorsed by the Board in June 2019 (Decision 15: Co-financing Arrangements for Inactivated Poliovirus Vaccine (IPV) Post 2020), and in December 2022 (Decision 10) on support for IPV and the IPV subsidy for Hexavalent vaccines. Under this approach:

- **High-Income and Upper Middle-Income Countries (UMICs)*** currently receiving support for IPV and Hexavalent vaccines will fully self-finance these programmes starting in 2026
- **Lower Middle-Income Countries (LMICs)*** currently receiving support for IPV and Hexavalent vaccines will receive a one-year grace period in 2026, followed by 50% co-financing in 2027, and be required to fully self-finance (100%) their IPV and Hexavalent programmes from 2028 onwards. Subsequently, newly designated FSF countries will receive a one-year grace period, followed by 50% co-financing in year two, and be required to fully self-finance (100%) from year three onwards.
- **In the event of an outbreak, a country's funding transition requirements may be reviewed.**

Decision 11: Funding Policy Review (5/5)

- g) **Rescind** the exceptional co-financing arrangements for malaria vaccines, as endorsed by the Board in December 2022 (Decision 19, item c) and **approve** the following co-financing requirements for malaria vaccine support as from 2026:
- For initial self-financing countries: Country co-financing follows the co-financing policy (\$0.20 per dose);
 - For preparatory transition countries: Country co-financing starts at US \$0.20 per dose in the first year of introduction and the co-financing per dose increases by 30% annually; and
 - For accelerated transition countries: Country co-financing follows the co-financing policy, with linear increase to reach 100% of vaccines costs in the first year of the fully self-financing phase.

Decision 12: Update on Mpox

The Gavi Alliance Board:

- a) **Approved** the opening of a funding window for the establishment of an mpox programme through an emergency stockpile for i) reactive vaccination in an outbreak setting and ii) potential repurposing of stockpile doses at risk of expiring for preventive vaccination in at-risk groups contingent on SAGE recommendations;
- b) **Noted** ongoing efforts to address data gaps, including the stockpile sizing learning agenda and the collaborative design of the global stockpile, shaping the final programme and financial estimates.

Decision 13: Respiratory Syncytial Virus (RSV) Investment Case

The Gavi Alliance Board:

- a) **Approved** the opening of a funding window for the establishment of an RSV maternal vaccine programme to protect infants;
- b) **Noted** that the initial cost estimates associated with the above approval for the period 2026-2030 are US\$ 14.8 million. Future financial forecasts will reflect potential changes in the underlying assumptions of these estimates.

Decision 14: Approach to Fragile and Humanitarian Settings

The Gavi Alliance Board:

Approved the Fragile and Humanitarian (F&H) approach for Gavi 6.0 as outlined in Annex B to Doc 10, as amended by the Board in its Gavi 6.0 recalibration, including a US\$ 150 million reduction of the additional cost to fully deliver on the ambition of the F&H approach, to be applied with proportionality and fungibility across: a) Gavi Resilience Mechanism, b) support for traditional vaccines, and c) catch-up of missed children up to age 5.

Decision 15: Evolution of Gavi's Partnership Approach

The Gavi Alliance Board:

- a) **Approved** the evolution of the Partnership Approach described in Annex D to Doc 11, as amended by the Board in its Gavi 6.0 recalibration, including a US\$ 100 million reduction of the Foundational Fund to be applied proportionately across the three guardrails: a) Country Foundations [to US\$ 154 million], b) Global and Regional Foundations [to US\$ 159 million] and c) Global and Regional Solutions [to US\$ 80 million].
- b) **Approved** the country foundational functions component of the Partnerships Accountability Framework (PAF) described in Annex C to Doc 11.

Thank you